MitchellGarrisonMD

Oncology • Omak, WA

Wenatchee Valley Medical Center

Join to view full profile

Dr. Garrison is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Garrison's full profile

Already have an account?

Office
916 Koala Dr
Omak, WA 98841
Phone+1 509-667-7538

Fax+1 509-664-3417
Is this information wrong?

Education & Training

San Antonio Uniformed Services Health Education ConsortiumFellowship, Hematology and Medical Oncology, 1998 - 2001
Madigan Army Medical CenterResidency, Internal Medicine, 1995 - 1998
Boston University School of MedicineClass of 1995

Certifications & Licensure

WA State Medical License 2006 - 2025
TX State Medical License 2002 - 2008
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast Cancer Start of enrollment: 2008 Apr 23
Completed
Phase 2
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting Start of enrollment: 2010 Dec 02
Completed
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer Start of enrollment: 2012 Apr 01
Terminated
Phase 2
A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL) Start of enrollment: 2012 Oct 31
Completed
Phase 2
LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib Start of enrollment: 2013 Jun 28
Completed
Phase 3
Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma Start of enrollment: 2013 Dec 13
Active, not recruiting
Phase 3
Feasibility and Outcomes of Allogeneic HCT Compared to Chemotherapy in Older AML Patients Start of enrollment: 2013 Jul 19
Completed
Decitabine and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, or Myeloproliferative Neoplasm Start of enrollment: 2014 Jun 01
Completed
Not Applicable
Join now to see all

Publications & Presentations

PubMed

5 citations
An 8-year pragmatic observation evaluation of the benefits of allogeneic HCT in older and medically infirm patients with AML.
Mohamed L Sorror, Ted A Gooley, Barry E Storer, Aaron T Gerds, Mikkael A Sekeres, Bruno C Medeiros, Eunice S Wang, Paul J Shami, Kehinde Adekola, Selina Luger, Maria R...> ;Blood. 2023 Jan 19
Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemia.
Mohamed L Sorror, Barry E Storer, Amir T Fathi, Andrew Brunner, Aaron T Gerds, Mikkael A Sekeres, Sudipto Mukherjee, Bruno C Medeiros, Eunice S Wang, Pankit Vachhani, ...> ;Blood. 2021 Aug 5
21 citations
Cantuzumab mertansine in a three-times a week schedule: a phase I and pharmacokinetic study
Jordi Rodon, Mitchell Garrison, Lisa A. Hammond, Johann S. de Bono, Lon Smith, Leonardo Forero, Desirée Hao, Chris H. Takimoto, John M. Lambert, Lini Pandite, Maria Ho...> ;Cancer Chemotherapy and Pharmacology. 2008 Feb 27
37 citations
Phase I and pharmacokinetic study of tasidotin hydrochloride (ILX651), a third-generation dolastatin-15 analogue, administered weekly for 3 weeks every 28 days in pati...
Alain C. Mita, Lisa A. Hammond, Peter L. Bonate, Geoffrey R. Weiss, Heather McCreery, Samira Syed, Mitchell Garrison, Quincy Siu-Chung Chu, J. De-Bono, Christopher B. ...> ;Clinical Cancer Research. 2006 Sep 1
1 citations
A phase I and pharmacokinetic study of the nonpolyglutamatable thymidylate synthase inhibitor ZD9331 plus docetaxel in patients with advanced solid malignancies.
Garry Schwartz, Christopher B. Jones, Mitchell Garrison, Amita Patnaik, Chris H. Takimoto, Heather McCreery, Michael Skinner, Anthony W. Tolcher, Eric K. Rowinsky> ;Investigational New Drugs. 2004 Nov 1
14 citations
A Phase I and Pharmocokinetic Study of Exatecan Mesylate Administered as a Protracted 21-Day Infusion in Patients with Advanced Solid Malignancies
Mitchell Garrison, Lisa A. Hammond, Charles E. Geyer, Garry Schwartz, Anthony W. Tolcher, Leslie Smetzer, Jose A. Figueroa, M. P. Ducharme, John Coyle, Chris H. Takimo...> ;Clinical Cancer Research. 2003 Jul 1
1 citations
Challenging cases and diagnostic dilemmas: case 1. Tracheal compression in Hodgkin's disease.
Mitchell A. Garrison, Christopher Glanton, Mark Rasnke, Michael E. Smith, Deborah L. Ornstein> ;Journal of Clinical Oncology. 2002 Aug 1
5 citations
Hypercalcemia mediated by parathyroid hormone-related protein as an early manifestation of pancreatic adenocarcinoma metastasis: a case report.
Mark Rasnake, Christopher Glanton, Deborah L. Ornstein, Michael B. Osswald, Mitchell Garrison> ;American Journal of Clinical Oncology. 2001 Aug 1
Join now to see all

Lectures

Limitations to Receiving Allogeneic Hematopoietic Cell Transplantation for Treatment of Acute Myeloid Leukemia: A Large Multi-Center Prospective Longitudinal Observati...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Survival Differences Among Patients (pts) with Acute Myeloid Leukemia (AML) Treated with Allogeneic Hematopoietic Cell Transplantation (HCT) Versus Non-HCT Therapies: ...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Hospital Affiliations

Confluence Health/Central Washington HospitalWenatchee, Washington
Confluence Health/Wenatchee Valley HospitalWenatchee, Washington

MitchellGarrisonMD

Dr. Garrison is on Doximity

Education & Training

Certifications & Licensure

Awards, Honors, & Recognition

Clinical Trials

Publications & Presentations

Hospital Affiliations

Viewing the full profile is available to verified healthcare professionals only.